AbbVie - ABBV Stock Forecast, Price & News

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Trading Up 0.8 %

NYSE:ABBV opened at $142.08 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.75 and a debt-to-equity ratio of 4.15. AbbVie has a 12 month low of $105.56 and a 12 month high of $175.91. The company has a market cap of $251.21 billion, a PE ratio of 20.12, a price-to-earnings-growth ratio of 3.94 and a beta of 0.70. The company has a 50 day simple moving average of $147.08 and a two-hundred day simple moving average of $150.21.

AbbVie (NYSE:ABBV - Get Rating) last issued its quarterly earnings data on Friday, July 29th. The company reported $3.51 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.42 by $0.09. AbbVie had a net margin of 22.03% and a return on equity of 158.41%. The firm had revenue of $14.58 billion during the quarter, compared to the consensus estimate of $14.64 billion. During the same quarter in the previous year, the firm posted $3.11 EPS. The company's revenue for the quarter was up 4.5% compared to the same quarter last year. Research analysts forecast that AbbVie will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Shareholders of record on Friday, July 15th will be paid a $1.41 dividend. This represents a $5.64 annualized dividend and a yield of 3.97%. The ex-dividend date of this dividend is Thursday, July 14th. AbbVie's payout ratio is currently 79.89%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Atlantic Securities lowered their target price on shares of AbbVie from $178.00 to $162.00 and set a "neutral" rating for the company in a report on Monday, August 1st. BMO Capital Markets lifted their target price on shares of AbbVie from $161.00 to $174.00 and gave the company an "outperform" rating in a report on Monday, April 25th. Daiwa Capital Markets lowered shares of AbbVie from an "outperform" rating to a "neutral" rating and set a $150.00 target price for the company. in a report on Friday, May 6th. UBS Group lowered their target price on shares of AbbVie from $154.00 to $146.00 and set a "neutral" rating for the company in a report on Monday, August 1st. Finally, Wells Fargo & Company lifted their target price on shares of AbbVie from $165.00 to $200.00 in a report on Monday, May 2nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $159.63.

Insiders Place Their Bets

In other news, EVP Henry O. Gosebruch sold 83,960 shares of the company's stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $155.00, for a total transaction of $13,013,800.00. Following the sale, the executive vice president now directly owns 16,623 shares in the company, valued at approximately $2,576,565. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Vice Chairman Michael Severino sold 79,801 shares of the stock in a transaction that occurred on Monday, May 23rd. The shares were sold at an average price of $150.90, for a total transaction of $12,041,970.90. Following the transaction, the insider now directly owns 152,103 shares in the company, valued at $22,952,342.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Henry O. Gosebruch sold 83,960 shares of the stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $155.00, for a total transaction of $13,013,800.00. Following the transaction, the executive vice president now owns 16,623 shares in the company, valued at $2,576,565. The disclosure for this sale can be found here. Insiders have sold a total of 263,761 shares of company stock worth $40,500,771 in the last 90 days. 0.08% of the stock is currently owned by corporate insiders.